Non-invasive profiling of the tumour microenvironment with spatial ecotypes
LiquidCell Dx is building the first truly comprehensive cancer test that includes the tumor microenvironment — from a simple blood draw
LiquidCell Dx provides a complete picture of the tumor and its microenvironment in a cost-effective and scalable liquid biopsy. By measuring what existing diagnostics miss — the tumor microenvironment — we predict therapy response with unprecedented accuracy.
Today's tumor profiling tools focus narrowly on the tumor itself — mutations, genomic profiles, individual biomarkers. But molecularly similar tumors behave very differently, and the reason lies outside the tumor cell.
Existing tools to profile this spatial ecosystem require invasive tissue biopsies or lack the resolution to capture its complexity. LiquidCell Dx looks at the whole cancer spatial ecosystem — not just the tumor — from a simple blood draw.
The surrounding network of immune cells, stromal cells, vasculature, and signaling — shapes whether a therapy will work. It can block or enable treatment response across immunotherapy, ADCs, and targeted therapies.
Same seed, restrictive ecosystem
limited growth
Same seed, permissive ecosystem
aggressive spread
Proprietary integrated AI platform that decodes spatial ecosystem biology to guide treatment decisions and drug development.
A non-invasive liquid biopsy captures signals from both the tumor and its surrounding microenvironment.
Our Detection AI maps signals to nine biologically interpretable states. Signals reflect hallmark features of the tumor microenvironment.
High-resolution profiling of the tumor microenvironment with spatial ecotypes
Patient samples are classified into Spatial Ecotypes and translated into a clear, clinically relevant report.
We are physician-scientists, computational biologists, and biotech operators with deep expertise across spatial transcriptomics, cell-free DNA biology, and cancer profiling and monitoring. Our founding science introduced the spatial ecotype framework and the methods that make it readable from blood. Together, we built LiquidCell Dx to bring spatial tumor microenvironment profiling and monitoring out of the research lab and into routine clinical practice.
IDT · Ultima Genomics · MIT · Foundation Medicine · 10x Genomics · Helicos · Rosa Bio
Memorial Sloan Kettering Cancer Center · Foundation Medicine · EQRx
Stanford Medicine · Mayo Clinic · MIT · Droplet Biosciences
Stanford Medicine · CAPP Med · CiberMed
We're building the future of cancer diagnostics with clinical, pharmaceutical, and diagnostic partners.
Clinical trial collaborations and companion diagnostic development
Academic and clinical validation studies across tumor types
Integration with existing genomic profiling workflows and laboratory infrastructure
